|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.47 HKD | +7.83% |
|
+8.92% | -3.14% |
| Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
| Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
Ocumension Therapeutics reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 246.37 million compared to CNY 158.96 million a year ago. Net loss was CNY 379.79 million compared to CNY 402.64 million a year ago.
Basic loss per share from continuing operations was CNY 0.59 compared to CNY 0.64 a year ago. Diluted loss per share from continuing operations was CNY 0.59 compared to CNY 0.64 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -3.14% | 573M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
OCUMENSION THERAPEUTICS 
